渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BIIB 渤健公司

休市中 08-14 16:00:00 EDT

209.83

-0.82

-0.39%

盘后210.03

+0.20+0.10%

19:37 EDT

最高210.79	最低208.22	成交量55.47万
今开210.01	昨收210.65	日振幅1.22%
总市值309.79亿	流通市值309.11亿	总股本1.48亿
成交额1.16亿	换手率0.38%	流通股本1.47亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BIIB","market":"US","secType":"STK","nameCN":"渤健公司","latestPrice":209.83,"timestamp":1786737600000,"preClose":210.65,"halted":0,"volume":554668,"hourTrading":{"tag":"盘后","latestPrice":210.0316,"preClose":209.83,"latestTime":"19:37 EDT","volume":44678,"amount":9374779.8337,"timestamp":1786750655146,"change":0.2016,"changeRate":0.000961,"amplitude":0.001962},"delay":0,"changeRate":-0.0038927130310941996,"floatShares":147314660,"shares":147637117,"eps":5.63,"marketStatus":"休市中","change":-0.82,"latestTime":"08-14 16:00:00 EDT","open":210.01,"high":210.79,"low":208.22,"amount":116335739.06588,"amplitude":0.0122,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":5.63,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1786953600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":685080000000,"exchange":"NASDAQ","adjPreClose":210.65,"preHourTrading":{"tag":"盘前","latestPrice":210.21,"preClose":210.65,"latestTime":"09:29 EDT","volume":269,"amount":56594.74591,"timestamp":1786714199999,"change":-0.44,"changeRate":-0.002089,"amplitude":0.019878},"postHourTrading":{"tag":"盘后","latestPrice":210.0316,"preClose":209.83,"latestTime":"19:37 EDT","volume":44678,"amount":9374779.8337,"timestamp":1786750655146,"change":0.2016,"changeRate":0.000961,"amplitude":0.001962},"volumeRatio":0.6711440570945221,"impliedVol":0.3122,"impliedVolPercentile":0.0239},"requestUrl":"/m/hq/s/BIIB","defaultTab":"news","newsList":[{"id":"2655917978","title":"美股异动 | 二季度营收及每股收益超预期 百健(BIIB.US)上涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2655917978","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655917978?lang=zh_cn&edition=full","pubTime":"2026-07-29 23:17","pubTimestamp":1785338223,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，百健(BIIB.US)股价上涨，截至发稿，涨幅超5%。消息面上，该公司二季度营收同比增长3.8%至27亿美元，超出预期2.4亿美元；每股收益为3.60美元，超出预期1.57美元。得益于新收购的肾脏及眼科疾病药物的销售增长，成功弥补了多发性硬化症(MS)药物收入下滑的影响，公司季度营收和经调整后收益均超出了分析师的预期。同时，公司上调了全年营收展望，称目前预计销售额将实现中个位数百分比的增长，而非此前预测的下降中个位数百分比。然而，百健下调了调整后盈利指引，以反映与收购相关的成本和里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473801.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"美股异动 | 二季度营收及每股收益超预期 百健(BIIB.US)上涨超5%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144361358","title":"异动解读 | 业绩超预期且上调全年营收指引，渤健公司盘中大涨5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=1144361358","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144361358?lang=zh_cn&edition=full","pubTime":"2026-07-29 21:43","pubTimestamp":1785332627,"startTime":"0","endTime":"0","summary":"渤健公司今日盘中股价大涨5.03%，成为市场关注焦点。公司同时上调了全年营收展望，预计销售额将实现中个位数百分比的增长，逆转了此前下降的预测，标志着其收购驱动转型战略初见成效。此外，巴克莱将渤健的目标价从185美元上调至200美元，进一步提振了市场信心。尽管公司因收购Apellis相关的费用下调了2026年调整后每股收益预期，但投资者更关注其新药组合的强劲增长势头，以及高剂量Spinraza转换进度超预期等积极信号。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655860932","title":"老药衰退新药接棒！收购驱动转型初见成效，百健(BIIB.US)上调全年营收指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2655860932","media":"智通财经","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655860932?lang=zh_cn&edition=full","pubTime":"2026-07-29 20:10","pubTimestamp":1785327014,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百健公布的季度营收和经调整后收益均超出了分析师的预期，这得益于新收购的肾脏及眼科疾病药物的销售增长，成功弥补了多发性硬化症药物收入下滑的影响。然而，百健下调了调整后盈利指引，以反映与收购相关的成本和里程碑付款。百健指出，若剔除这些项目，公司的基础收益预期本应每股增加 0.60 美元。百健表示，这两款药物在该季度剩余时间内为其带来了近 1.28 亿美元的收入。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1473711.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173868024","title":"渤健公司：因整合Apellis，截至2026年6月30日止三个月及六个月确认1.532亿美元税前重组净支出","url":"https://stock-news.laohu8.com/highlight/detail?id=1173868024","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173868024?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:46","pubTimestamp":1785321986,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）披露，为推进与Apellis的整合进程，在截至2026年6月30日的三个月及六个月期间内，公司确认了高达1.532亿美元的净税前重组费用。这笔支出旨在优化资源配置，加速业务融合，并应对市场结构性变化。重组举措覆盖了运营调整、人员精简及资产处置等多个方面，以提升长期竞争力。具体而言，这些费用主要源于整合相关活动，包括关闭重叠设施、削减冗余岗位以及处理遗留合同等。公司方面强调，尽管短期面临财务压力，但此举是实现战略协同、释放合并后价值的关键步骤。未来，渤健将继续评估整合进度，并适时调整财务预期。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LU0320765992.SGD","BIIB","BK4533","BK4532","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BK4139","IE00B894F039.SGD","LU0234570918.USD","LU0109394709.USD","BK4588","PBE","BMED","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1147971918","title":"渤健公司：中东冲突未对2026年上半年经营业绩产生实质性影响","url":"https://stock-news.laohu8.com/highlight/detail?id=1147971918","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1147971918?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:43","pubTimestamp":1785321809,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）最新披露，中东地区的地缘冲突局势，并未对其截至2026年6月30日的三个月及六个月期间的经营业绩，构成任何实质性影响。这一表态，清晰地向市场传递了其业务在外部动荡环境下的韧性。从短期业绩到中期财务状况，这家生物科技巨头均未因该地区的不确定性而遭受显著冲击。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","BK4532","LU0889565916.HKD","IE00B894F039.SGD","PBE","BK4588","IE00B19Z9P08.USD","BMED","LU0320765992.SGD","LU0234570918.USD","BK4139","LU0109394709.USD","IE00B19Z9Z06.USD","BK4585","BK4533"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1138863286","title":"渤健：高剂量Spinraza转换进度超预期，已覆盖所有已上市地区","url":"https://stock-news.laohu8.com/highlight/detail?id=1138863286","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1138863286?lang=zh_cn&edition=full","pubTime":"2026-07-29 18:02","pubTimestamp":1785319323,"startTime":"0","endTime":"0","summary":"渤健公司（Biogen）宣布，其高剂量Spinraza治疗方案在已上市的所有地理区域中，转换进度均超出公司预期。这一进展表明，患者对该剂型的接受度与医疗系统的适应速度均优于先前的规划。渤健表示，高剂量方案的推广正按计划稳步推进，且在某些市场甚至提前实现了预设目标。这一趋势反映出公司对神经肌肉疾病治疗的持续优化能力，以及市场对创新疗法的积极反馈。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","IE00B19Z9Z06.USD","PBE","IE00B894F039.SGD","BK4533","BK4585","BK4532","BK4588","BIIB","LU0320765992.SGD","BK4139","BMED","LU0109394709.USD","LU0889565916.HKD","IE00B19Z9P08.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198085382","title":"财报前瞻｜渤健公司本季度营收预计增5.93%，机构观点看多占优","url":"https://stock-news.laohu8.com/highlight/detail?id=1198085382","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198085382?lang=zh_cn&edition=full","pubTime":"2026-07-22 09:54","pubTimestamp":1784685267,"startTime":"0","endTime":"0","summary":"渤健公司将于2026年07月29日盘前发布最新季度财报，市场关注Leqembi商业化进展与利润率变化对单季表现的影响。市场一致预期本季度营收24.61亿美元，同比增长5.93%；调整后每股收益3.09美元，同比下降20.05%；息税前利润6.07亿美元，同比下降14.80%。上季营收24.78亿美元，同比增长1.93%；毛利率75.37%；归属于母公司股东的净利润3.19亿美元，同比增长32.85%；净利率12.89%；调整后每股收益3.57美元，同比增长18.21%。从近期可获取的机构观点看，看多意见占优。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"财报前瞻｜渤健公司本季度营收预计增5.93%，机构观点看多占优","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170294160","title":"异动解读｜渤健公司盘中上涨5.03%，加拿大药品管理机构建议将Leqembi纳入公共医保覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=1170294160","media":"行情直击","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1170294160?lang=zh_cn&edition=full","pubTime":"2026-07-17 01:15","pubTimestamp":1784222152,"startTime":"0","endTime":"0","summary":"7月17日，渤健公司盘中上涨5.03%，报207.24美元/股，成交额1.62亿美元。消息面上，加拿大药品管理机构正式认可Leqembi的临床价值，建议将其纳入公共医保覆盖范围用于治疗早期阿尔茨海默病。Leqembi由渤健与卫材共同开发，一季度收入已同比大增74%至1.68亿美元。此前一个交易日渤健曾因Diranersen二期未达主要终点而下跌逾7%，本次反弹显示市场对Leqembi商业化前景的信心有所修复。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169524809","title":"卫材：加拿大药品管理机构认可Leqembi临床价值，建议将早期阿尔茨海默病纳入公共医保覆盖","url":"https://stock-news.laohu8.com/highlight/detail?id=1169524809","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1169524809?lang=zh_cn&edition=full","pubTime":"2026-07-16 20:17","pubTimestamp":1784204253,"startTime":"0","endTime":"0","summary":"加拿大药品管理机构已正式认可Leqembi的临床价值，并建议将其纳入公共医保覆盖范围，用于治疗早期阿尔茨海默病。这一积极建议标志着该创新疗法在获得更广泛患者可及性的道路上迈出了关键一步。Leqembi由卫材与渤健公司共同开发，是一种针对阿尔茨海默病潜在病理机制的靶向疗法。加拿大相关机构的认可，是基于其临床试验所展现出的减缓疾病进展的明确证据。此举若最终获得采纳，将显著减轻早期阿尔茨海默病患者及其家庭的经济负担。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0234570918.USD","BIIB","IE00B19Z9P08.USD","IE00B894F039.SGD","LU0320765992.SGD","BK4533","BK4532","LU0109394709.USD","IE00B19Z9Z06.USD","LU0889565916.HKD","BK4585","BK4139","BMED","PBE","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651946677","title":"a16z投资、百健CEO坐镇！心血管新药研发商Braveheart(BRVE.US)冲刺纳斯达克IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2651946677","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651946677?lang=zh_cn&edition=full","pubTime":"2026-07-15 21:35","pubTimestamp":1784122530,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，由 A16z 支持的临床阶段生物制药公司 Braveheart Bio Inc. 于周三向纳斯达克提交了 IPO 申请。这家心血管疾病药物开发商将寻求通过在纳斯达克全球市场销售股份来募集一笔尚未公布具体金额的资金。百健首席执行官克里斯托弗·维巴赫担任 Braveheart 的董事长。Braveheart 报告称，在 2026 年前三个月，其净亏损为 1430 万美元，并创造了约 1100 万美元的收入。相比之下，去年同期的前三个月净亏损为 9.9 万美元。Braveheart 将以股票代码“BRVE”进行交易。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1468128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"a16z投资、百健CEO坐镇！心血管新药研发商Braveheart(BRVE.US)冲刺纳斯达克IPO","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00B894F039.SGD","BK4533","LU0889565916.HKD","BK4588","BIIB","PBE","BK4532","LU0109394709.USD","BK4585","LU0234570918.USD","BMED","IE00B19Z9Z06.USD","LU0320765992.SGD","IE00B19Z9P08.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199762348","title":"Leqembi®真实世界领先研究在AAIC® 2026发布：超75%早期阿尔茨海默病患者在平均17个月治疗期内保持稳定，近7%出现改善","url":"https://stock-news.laohu8.com/highlight/detail?id=1199762348","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1199762348?lang=zh_cn&edition=full","pubTime":"2026-07-14 23:16","pubTimestamp":1784042182,"startTime":"0","endTime":"0","summary":"Leqembi®真实世界领先研究在AAIC® 2026年会上公布的数据显示，在该研究中，超过75%的早期阿尔茨海默病患者在接受平均17个月的治疗后病情保持稳定，同时有近7%的患者病情出现改善。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4533","IE00B19Z9Z06.USD","BK4139","BMED","BK4585","BIIB","IE00B894F039.SGD","LU0109394709.USD","BK4588","LU0320765992.SGD","IE00B19Z9P08.USD","PBE","LU0234570918.USD","LU0889565916.HKD","BK4532"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125542301","title":"异动解读｜渤健公司盘中下跌7.06%，Diranersen二期CELIA完整数据公布后股价急挫","url":"https://stock-news.laohu8.com/highlight/detail?id=1125542301","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125542301?lang=zh_cn&edition=full","pubTime":"2026-07-14 22:24","pubTimestamp":1784039055,"startTime":"0","endTime":"0","summary":"消息面上，公司在阿尔茨海默病协会国际会议上公布了Diranersen的二期CELIA研究完整数据，并宣布将推进该药至三期临床。尽管数据显示Diranersen在Tau蛋白降低和认知获益方面表现积极，但该研究此前已确认未达到主要终点——CDR-SB评分的剂量反应评估未获满足，市场对其注册开发路径仍存疑虑。摩根士丹利此前按30%成功概率估算Diranersen约贡献公司2035年总收入的10%，市场对该药物的风险定价仍在消化调整中。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132952984","title":"渤健公司于AAIC公布Celia二期数据：Diranersen在早期阿尔茨海默病中展现显著临床获益与强劲Tau蛋白降低","url":"https://stock-news.laohu8.com/highlight/detail?id=1132952984","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132952984?lang=zh_cn&edition=full","pubTime":"2026-07-14 21:16","pubTimestamp":1784034993,"startTime":"0","endTime":"0","summary":"渤健公司近日在阿尔茨海默病协会国际会议上公布了其候选药物Diranersen的Celia二期研究数据。结果显示，该药物在治疗早期阿尔茨海默病患者时，不仅带来了具有临床意义的积极结局，更实现了Tau蛋白水平的强劲降低。这一积极信号为针对这一复杂神经退行性疾病的靶向治疗带来了新的希望。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4532","LU0234570918.USD","IE00B894F039.SGD","BK4588","LU0889565916.HKD","PBE","BMED","BK4533","LU0109394709.USD","LU0320765992.SGD","BK4139","IE00B19Z9Z06.USD","IE00B19Z9P08.USD","BK4585","BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651106049","title":"百健(BIIB.US)：将推进阿尔茨海默病药物Diranersen至3期临床。","url":"https://stock-news.laohu8.com/highlight/detail?id=2651106049","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651106049?lang=zh_cn&edition=full","pubTime":"2026-07-14 21:15","pubTimestamp":1784034918,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU0320765992.SGD","LU0889565916.HKD","IE00B19Z9Z06.USD","LU0234570918.USD","BIIB","BK4585","BK4532","BK4588","BMED","IE00B19Z9P08.USD","BK4139","LU0109394709.USD","PBE","BK4533","IE00B894F039.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651754101","title":"FDA批准勃健(BIIB)阿尔茨海默病新药皮下剂型 拓展居家治疗应用场景","url":"https://stock-news.laohu8.com/highlight/detail?id=2651754101","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2651754101?lang=zh_cn&edition=full","pubTime":"2026-07-14 16:31","pubTimestamp":1784017876,"startTime":"0","endTime":"0","summary":"本次剂型获批基于严谨的临床对比数据，临床试验证实，Leqembi皮下注射剂型的治疗效果、药效稳定性与原有静脉注射剂型高度一致，疗效水平无显著差异。","market":"other","thumbnail":"https://static.szfiu.com/news/20250107/NDk1MmZiNjQzNDA1OTQ5NDMzMQ==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NDk1MmZiNjQzNDA1OTQ5NDMzMQ==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"302523","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IBRN","ESALF","IE00B19Z9P08.USD","LU0320765992.SGD","IE00B894F039.SGD","LU0109394709.USD","BK4007","LU0234570918.USD","BK4532","BK4139","BMED","IE00B19Z9Z06.USD","PBE","ESAIY","BIIB","LABU","BK4588","BK4533","MNTL","LU0889565916.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191345039","title":"FDA批准Leqembi Iqlik®（lecanemab-irmb）皮下注射剂作为早期阿尔茨海默病的起始剂量","url":"https://stock-news.laohu8.com/highlight/detail?id=1191345039","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191345039?lang=zh_cn&edition=full","pubTime":"2026-07-14 05:37","pubTimestamp":1783978636,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准Leqembi Iqlik®（lecanemab-irmb）皮下注射剂，作为治疗早期阿尔茨海默病的起始剂量方案。这一决定为患者提供了一种新的、便捷的给药选择，有望改善治疗的可及性与依从性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB","BK4533","BK4532","BK4139","BMED","LU0109394709.USD","LU0234570918.USD","LU0320765992.SGD","IE00B894F039.SGD","PBE","LU0889565916.HKD","IE00B19Z9Z06.USD","BK4588","IE00B19Z9P08.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175822678","title":"异动解读｜渤健公司盘中上涨5.26%，FDA批准Leqembi皮下注射新起始给药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1175822678","media":"行情直击","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1175822678?lang=zh_cn&edition=full","pubTime":"2026-07-14 03:44","pubTimestamp":1783971880,"startTime":"0","endTime":"0","summary":"消息面上，FDA正式批准Leqembi皮下注射剂型用于治疗阿尔茨海默病的新起始给药方案。此前一日，渤健与卫材在阿尔茨海默病协会国际会议上公布数据显示，每周一次500mg皮下注射Leqembi在药物暴露量上与已获批的静脉输注起始方案生物等效，支持相当的淀粉样蛋白清除效果、临床疗效及安全性。皮下注射剂型获批为患者提供了更便捷的居家替代方案，有望进一步推动Leqembi销售增长——该药一季度收入已同比大增74%至1.68亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120715125","title":"FDA批准Leqembi皮下注射剂型治疗阿尔茨海默病的新起始给药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1120715125","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1120715125?lang=zh_cn&edition=full","pubTime":"2026-07-14 02:08","pubTimestamp":1783966119,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）已批准Leqembi皮下注射剂型用于治疗阿尔茨海默病的新起始给药方案。这一监管决定为患者提供了更便捷的治疗选择，有望改善用药依从性。\nLeqembi由渤健公司（Biogen）与合作伙伴共同开发，此次新方案的获批标志着其在阿尔茨海默病治疗领域取得了又一重要进展。皮下注射剂型相较于静脉输注，能简化给药流程，为患者和护理人员带来便利。\n新起始剂量方案的确定基于临床数据，旨在优化治疗效果并管理潜在风险。随着全球阿尔茨海默病患者数量持续增长，此类创新疗法的推进对满足未竟医疗需求具有重要意义。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B894F039.SGD","BK4532","BK4588","BMED","LU0889565916.HKD","LU0109394709.USD","BK4139","IE00B19Z9Z06.USD","LU0234570918.USD","LU0320765992.SGD","BIIB","IE00B19Z9P08.USD","BK4533","PBE","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127250118","title":"异动解读｜渤健公司盘中上涨5.86%，宣布暂停大部分Apellis研究项目聚焦核心管线","url":"https://stock-news.laohu8.com/highlight/detail?id=1127250118","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1127250118?lang=zh_cn&edition=full","pubTime":"2026-06-26 23:01","pubTimestamp":1782486100,"startTime":"0","endTime":"0","summary":"6月26日，渤健公司盘中上涨5.86%，报213.79美元/股，成交额1.01亿美元。消息面上，渤健公司当日宣布已决定暂停或终止对绝大部分传统Apellis研究项目的投资，并对原属Apellis的临床及临床前产品组合进行全面审查，以评估其与公司战略的契合度。市场将此举解读为公司主动优化研发投入、聚焦更具潜力的核心管线，有助于改善资源配置效率。此前渤健已于今年完成对Apellis的收购及以最高10亿美元收购RayThera，持续扩展免疫学布局。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133029467","title":"渤健公司发言人：对前Apellis临床及临床前产品组合进行全面审查，以进一步评估战略契合度","url":"https://stock-news.laohu8.com/highlight/detail?id=1133029467","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1133029467?lang=zh_cn&edition=full","pubTime":"2026-06-26 19:55","pubTimestamp":1782474923,"startTime":"0","endTime":"0","summary":"渤健公司发言人表示，公司目前正在对原属Apellis的临床及临床前产品组合进行全面审查。此举旨在深入评估这些资产与公司自身发展战略的契合程度，从而为未来的战略决策提供依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0889565916.HKD","IE00B19Z9P08.USD","IE00B19Z9Z06.USD","BIIB","BK4533","LU0109394709.USD","IE00B894F039.SGD","BK4585","LU0234570918.USD","BK4532","LU0320765992.SGD","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biogen.com;investors.biogen.com","stockEarnings":[{"period":"1week","weight":0.0091},{"period":"1month","weight":0.0638},{"period":"3month","weight":0.0875},{"period":"6month","weight":0.0677},{"period":"1year","weight":0.555},{"period":"ytd","weight":0.1923}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0503},{"period":"6month","weight":0.1387},{"period":"1year","weight":0.2037},{"period":"ytd","weight":0.1385}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Biogen Inc.于1985年在加利福尼亚州以IDEC制药公司的名义成立，并于1997年重新注册为特拉华州公司。2003年，收购了Biogen, Inc.，并将公司名称更改为Biogen Idec Inc.。该公司是一家全球性生物制药公司，致力于为患有严重复杂疾病的人发现、开发和提供创新疗法。该公司拥有广泛的多发性硬化症（MS）药物组合，推出了首个获批治疗脊髓性肌萎缩症（SMA）的药物，共同开发了解决阿尔茨海默病定义病理学的治疗方法，并推出了首个获批的针对肌萎缩侧索硬化症（ALS）遗传原因的疗法。渤健还销售第一个也是唯一一个批准用于治疗16岁及以上成人和青少年的弗里德赖希共济失调（FA）的药物。其研发工作专注于神经病学、专业免疫学和罕见病，并得到内部项目、合作和收购的支持。该公司将生物制剂和生物仿制药商业化，并与领先的制药公司保持战略合作伙伴关系，以推进其产品组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.571429,"avgChangeRate":0.039226},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.00281},{"month":3,"riseRate":0.485714,"avgChangeRate":-0.023881},{"month":4,"riseRate":0.342857,"avgChangeRate":-0.019659},{"month":5,"riseRate":0.628571,"avgChangeRate":0.03345},{"month":6,"riseRate":0.485714,"avgChangeRate":0.019046},{"month":7,"riseRate":0.657143,"avgChangeRate":0.03199},{"month":8,"riseRate":0.6,"avgChangeRate":0.030765},{"month":9,"riseRate":0.5,"avgChangeRate":0.023197},{"month":10,"riseRate":0.542857,"avgChangeRate":0.058896},{"month":11,"riseRate":0.6,"avgChangeRate":0.018187},{"month":12,"riseRate":0.457143,"avgChangeRate":0.034185}],"exchange":"NASDAQ","name":"渤健公司","nameEN":"Biogen"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"渤健公司,BIIB,渤健公司股票,渤健公司股票老虎,渤健公司股票老虎国际,渤健公司行情,渤健公司股票行情,渤健公司股价,渤健公司股市,渤健公司股票价格,渤健公司股票交易,渤健公司股票购买,渤健公司股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"渤健公司(BIIB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供渤健公司(BIIB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}